Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences

Hepatology

Volumn 20, Issue 5, 1994, Pages 1359-1363

  Groszmann, Roberto J ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NITRIC OXIDE; OXYGEN;

ARTERIAL PRESSURE; EDITORIAL; HEPATIC COMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER DISEASE; PATHOPHYSIOLOGY; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION;

ANIMAL; ANOXEMIA; BLOOD CIRCULATION; HEART DISEASES; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERTENSION, PORTAL; LIVER DISEASES; RATS; VASODILATION;

EID: 0027938229     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.1840200538     Document Type: Editorial

References (64)

1. The cardiac output at rest in Laennec cirrhosis
2. Portal hypertension
3. Biology of portal hypertension
4. Pulmonary arteriovenous admixture and the hyperdynamic cardiovascular state in surgery for portal‐hypertension
5. Physiologic determinants of operative survival after portocaval shunt
6. Decreased pressor reactivity to angiotensin II in cirrhotic rats: evidence for a post‐receptor defect in angiotensin action
7. Splanchnic hemodynamics in chronic portal hypertension
8. Hyperglucagonemia in Laennec's cirrhosis: the role of portal‐systemic shunting
9. Hemodynamic effects of glucagon in portal hypertension
10. Role of glucagon in splanchnic hyperemia of chronic portal hypertension
11. Chronic octreotide treatment ameliorates peripheral vasodilatation and prevents sodium retention in portal hypertensive rats
12. Glucagon hinders the effects of somatostatin on portal hypertension
13. Peripheral hemodynamics in cirrhotic patients with and without ascites: effect of octreotide [Abstract]
14. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats
15. Pharmacologic control of portal hypertension
16. Nitric oxide mediates in vitro hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats
17. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats
18. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition
19. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension
20. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal‐hypertensive rats
21. The nitric oxide synthase family of proteins
22. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lypopolysaccharides in the rat in vivo
23. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin
24. G‐methyl‐l‐arginine inhibits tumor necrosis factor induced hypotension: implications for the involvement of nitric oxide
25. Pro‐inflammatory cytoquines and strategies to prevent their effects
26. Pteridine biosynthesis in human endothelial cells
27. Hypotension and endotoxin‐induced alterations in calcitonin gene‐related peptide: modulation by dexamethasone
28. Treatment with anti‐tumor necrosis factor‐α polyclonal antibodies prevents the development of the hyperdynamic circulation and reduces portal pressure in portal‐hypertensive rats [Abstract]
29. Circulating tumor necrosis factor, interleukin‐1 and interleukin‐6 concentration in chronic alcoholic patients
30. Endotoxin and the hyperdynamic circulation of portal vein—ligated rats
31. Endotoximia in portal‐hypertensive rats [Abstract]
32. Bacterial translocation in acute and chronic portal hypertension
33. Bacterial translocation in the portal‐hypertensive rat: studies in basal conditions and on exposure to hemorrhagic shock
34. Bacterial translocation is increased in experimental cirrhosis [Abstract]
35. Enhanced expression of TNF‐α in patients with primary biliary cirrhosis
36. Increased blood flow through the portal system in cirrhotic rats
37. Circulatory changes in chronic liver disease
38. Hepatic blood flow in alcoholic liver disease measured by an indicator dilution technique
39. Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans in an operator‐blind echo‐Doppler study
40. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model
41. Pharmacology of portal‐systemic collaterals in portal hypertensive rats: role of the endothelium
42. Modulation of endothelium‐dependent responses by chronic alteration of blood flow
43. Propranolol ameliorates the development of portal‐systemic shunting in a chronic murine schistosomiasis model of portal hypertension
44. Pathogenesis of sodium and water retention in liver disease
45. ω‐nitro‐l‐arginine administration corrects peripheral vasodilation and systemic capillary hypotension, and ameliorates plasma volume expansion and sodium retention in portal‐hypertensive rats
46. Chronic octreotide treatment ameliorates peripheral vasodilatation and prevents sodium retention in portal hypertensive rats
47. Octreotide improves renal function, total exchangeable sodium and peripheral hemodynamics in cirrhotic patients with ascites [Abstract]
48. Pathogenesis of sodium retention in early cirrhosis of the liver: evidence for vascular overfilling
49. Peripheral arterial vasodilatation: determinants of functional spectrum of cirrhosis
50. Reduced central blood volume in cirrhosis
51. Role of central blood volume in the development of sodium retention in portal‐hypertensive rats [Abstract]
52. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal‐hypertensive rats
53. The hepatopulmonary syndrome: new name, old complexities
54. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy
55. Cerebral hemodynamic and changes in fulminant hepatic failure: a retrospective study
56. Cerebral blood flow and the hyperdynamic circulation of rats after portacaval anastomosis
57. Depressed left ventricular performance response to volume infusion in patients with sepsis and septic shock
58. Hepatocirculatory failure
59. Portal vein stenosis and cardiac impairment [Abstract]
60. Limited cardiac preload reserve in conscious cirrhotic rats
61. Tumor necrosis factor depresses myocardial function: results using in vitro assay of myocyte performance [Abstract]
62. The relation of alcoholic myopathy to cardiomyopathy